Final results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients

2022-02-08T10:38:01+00:00February 8th, 2022|

Final results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients Total responses CONTACT US Summary The purpose of this study is [...]

Efficacy analysis of triple-negative breast cancer patients treated with dendritic cell-cytokine-induced killer cell immunotherapy

2022-01-26T13:13:12+00:00January 26th, 2022|

Efficacy analysis of triple-negative breast cancer patients treated with dendritic cell-cytokine-induced killer cell immunotherapy Overall Survival CONTACT US Summary The study investigates the efficacy of dendritic cell-cytokine-induced killer (DC-CIK) [...]

Adjuvant treatment for triple-negative breast cancer: a retrospective study of immunotherapy with autologous cytokine- induced killer cells in 294 patients

2022-01-18T12:23:08+00:00January 18th, 2022|

Adjuvant treatment for triple-negative breast cancer: a retrospective study of immunotherapy with autologous cytokine- induced killer cells in 294 patients CIK treatment CONTACT US Summary The study aims to [...]

Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers

2021-12-16T07:03:26+00:00December 16th, 2021|

Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers Overall Survival CONTACT US Summary This study investigates the correlation of cytokines produced [...]

A phase-1/2 study of adenovirus-p53 transduced Dendritic Cell Vaccine in combination with Indoximod in metastatic solid tumors and invasive Breast Cancer

2021-11-22T14:44:11+00:00November 19th, 2021|

A phase-1/2 study of adenovirus-p53 transduced Dendritic Cell Vaccine in combination with Indoximod in metastatic solid tumors and invasive Breast Cancer Survival rate CONTACT US Summary [...]

Go to Top